Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846281 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
A Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT06846281: Recruiting Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
NCT06846281 is a Phase 3 study of Relapsing Multiple Sclerosis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 360 participants, below the 2,154-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06846281, a Phase 3 study of Relapsing Multiple Sclerosis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
Primary Outcome
Number of new/enlarging T2 lesions per year on MRI at month 24 (relative to baseline)
Conditions Studied
Interventions
- DRUG Ocrelizumab
- DRUG Remibrutinib oral treatment
Study Locations (20)
Florida
- Neurology of Central FL Res Ctr - Altamonte Springs
- University of Florida - Gainesville
- Neurology Associates PA - Maitland
- Aqualane Clinical Research - Naples
- Tallahassee Neurological Clinic - Tallahassee
Massachusetts
- Tufts Medical Center - Boston
- Lahey Hospital and Medical Center - Burlington
- Neurology Center of New England PC - Foxborough
Michigan
- Michigan Institute of Neurological - Farmington Hills
- Memorial HC Ins for Neuroscience - Owosso
Arizona
- Perseverance Research Center - Scottsdale
District of Columbia
- Medstar Washington Hospital Center - Washington D.C.
Illinois
- Rush University Medical Center - Chicago
Kansas
- University of Kansas Hospital - Kansas City
Maryland
- MedStar Montgomery Medical Center - Olney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2031-06-20 |
| Phase | Phase 3 |
What NCT06846281 shows while recruiting
NCT06846281 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, below the 2,154-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Ocrelizumab is the first listed.
NCT06846281 names 20 study sites across 13 states, led by Florida, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT06846281 about?
NCT06846281 is a clinical study titled "Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.". The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
What is the current status of trial NCT06846281?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2025-07-23. Estimated completion is 2031-06-20.
What conditions does trial NCT06846281 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT06846281?
The interventions under investigation include: Ocrelizumab (DRUG), Remibrutinib oral treatment (DRUG).
Who is sponsoring clinical trial NCT06846281?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06846281 being conducted?
This trial has 20 study locations across Arizona, District of Columbia, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06846281's enrollment target sits among peer trials
360 13th of 23 higher than 11 of 23 other Relapsing Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI